4-Fluoroselegiline Explained
| Drug Name: | 4-Fluoroselegiline |
| Cas Number: | 103596-43-6 |
| Pubchem: | 128418 |
| Chemspiderid: | 113833 |
| Synonyms: | Chinoin-175; Fludepryl; SR-96516-A; p-Fluoro-L-deprenyl |
| Iupac Name: | N-[1-(4-fluorophenyl)propan-2-yl]-N-methylprop-2-yn-1-amine |
| C: | 13 |
| H: | 16 |
| F: | 1 |
| N: | 1 |
| Smiles: | CC(CC1=CC=C(F)C=C1)N(C)CC#C |
| Stdinchi: | 1S/C13H16FN/c1-4-9-15(3)11(2)10-12-5-7-13(14)8-6-12/h1,5-8,11H,9-10H2,2-3H3 |
| Stdinchikey: | MUDUXRHPVDVWHU-UHFFFAOYSA-N |
| Density: | 1.024 ± 0.06 |
| Boiling Point: | 276.2 ± 25 |
4-Fluoroselegiline, or p-fluoro-L-deprenyl, is a substituted amphetamine designer drug. It is the 4-fluorinated derivate of selegiline.
Pharmacology
Pharmacodynamics
4-Fluoroselegiline is a selective and irreversible inhibitor of monoamine oxidase B and monoaminergic activity enhancer.[1] [2] [3]
A radiolabelled derivative incorporating 18F is used to study MAO-B inhibition in both in vivo and in vitro experiments.[4]
Pharmacokinetics
4-Fluoro-deprenyl is metabolized to 4-Fluoromethamphetamine and 4-Fluoroamphetamine, both of which are active. The levels of substituted amphetamine metabolites in the brain is three times higher following 4-fluoroselegiline administration compared to an equivalent dose of selegiline.[2]
Society and culture
Names
Synonyms of 4-fluoroselegiline or 4-fluorodeprenyl (the racemic form) include Chinoin-175, Fludepryl, and SR-96516-A.[5]
Notes and References
- Erdö F, Baranyi A, Takács J, Arányi P . August 2000 . Different neurorescue profiles of selegiline and p-fluoro-selegiline in gerbils . NeuroReport . 11 . 11 . 2597–2600 . 10.1097/00001756-200008030-00049 . 10943729 . 20944931.
- Yasar S, Gaal J, Justinova Z, Bergman J . October 2005 . Discriminative stimulus and reinforcing effects of p-fluoro-L-deprenyl in monkeys . Psychopharmacology . 182 . 1 . 95–103 . 10.1007/s00213-005-0063-y . 15990999 . 444126.
- Knoll J, Miklya I (1994). "Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition". Arch Int Pharmacodyn Ther. 328 (1): 1–15. PMID 7893186.
- Plenevaux A, Fowler JS, Dewey SL, Wolf AP, Guillaume M . The synthesis of no-carrier-added DL-4-[18F]fluorodeprenyl via the nucleophilic aromatic substitution reaction . International Journal of Radiation Applications and Instrumentation, Part A . 42 . 2 . 121–127 . January 1991 . 1648033 . 10.1016/0883-2889(91)90060-E .
- Book: Paul W, Szelenyi I . Szelenyi I . Inhibitors of Monoamine Oxidase B: Pharmacology and Clinical Use in Neurodegenerative Disorders . Milestones in Drug Therapy . Appendix I: Chemical Structures and Pharmacological Features of MAO-B Inhibitors . Birkhäuser Basel . Basel . 1993 . 978-3-0348-6349-0 . 2296-6056 . 339–358.
